109 related articles for article (PubMed ID: 31627704)
21. Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells.
Murphy LC; Peng B; Lewis A; Davie JR; Leygue E; Kemp A; Ung K; Vendetti M; Shiu R
J Mol Endocrinol; 2005 Apr; 34(2):553-66. PubMed ID: 15821116
[TBL] [Abstract][Full Text] [Related]
22. Extreme growth factor signalling can promote oestrogen receptor-alpha loss: therapeutic implications in breast cancer.
Gee JM; Giles MG; Nicholson RI
Breast Cancer Res; 2004; 6(4):162-3. PubMed ID: 15217488
[No Abstract] [Full Text] [Related]
23. STAT1 facilitates oestrogen receptor α transcription and stimulates breast cancer cell proliferation.
Hou Y; Li X; Li Q; Xu J; Yang H; Xue M; Niu G; Zhuo S; Mu K; Wu G; Li X; Wang H; Zhu J; Zhuang T
J Cell Mol Med; 2018 Dec; 22(12):6077-6086. PubMed ID: 30334368
[TBL] [Abstract][Full Text] [Related]
24. Most recent strategies targeting estrogen receptor alpha for the treatment of breast cancer.
Kumar N; Gulati HK; Sharma A; Heer S; Jassal AK; Arora L; Kaur S; Singh A; Bhagat K; Kaur A; Singh H; Singh JV; Bedi PMS
Mol Divers; 2021 Feb; 25(1):603-624. PubMed ID: 32886304
[TBL] [Abstract][Full Text] [Related]
25. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
[TBL] [Abstract][Full Text] [Related]
26. First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer.
Helms MW; Packeisen J; August C; Schittek B; Boecker W; Brandt BH; Buerger H
J Pathol; 2005 Jul; 206(3):366-76. PubMed ID: 15892165
[TBL] [Abstract][Full Text] [Related]
27. Molecular basis of distinct oestrogen responses in endometrial and breast cancer.
Baxter E; Windloch K; Kelly G; Lee JS; Gannon F; Brennan DJ
Endocr Relat Cancer; 2019 Jan; 26(1):31-46. PubMed ID: 30121621
[TBL] [Abstract][Full Text] [Related]
28. The ninth ENBDC Weggis meeting: growth and in-depth characterisation of normal and neoplastic breast cells.
Wiese KE; Amante RJ; Vivanco MD; Bentires-Alj M; Iggo RD
Breast Cancer Res; 2017 Aug; 19(1):96. PubMed ID: 28830566
[TBL] [Abstract][Full Text] [Related]
29. Blocking of oestrogen signals improves anti-tumour effect regardless of oestrogen receptor alpha expression in cancer cells.
Kajihara N; Ge Y; Seino KI
Br J Cancer; 2023 Oct; 129(6):935-946. PubMed ID: 37537255
[TBL] [Abstract][Full Text] [Related]
30. Estrogen-independent Myc overexpression confers endocrine therapy resistance on breast cancer cells expressing ERαY537S and ERαD538G mutations.
Yu L; Wang L; Mao C; Duraki D; Kim JE; Huang R; Helferich WG; Nelson ER; Park BH; Shapiro DJ
Cancer Lett; 2019 Feb; 442():373-382. PubMed ID: 30419347
[TBL] [Abstract][Full Text] [Related]
31. Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion.
Platet N; Cathiard AM; Gleizes M; Garcia M
Crit Rev Oncol Hematol; 2004 Jul; 51(1):55-67. PubMed ID: 15207254
[TBL] [Abstract][Full Text] [Related]
32. Pterostilbene mediates neuroprotection against oxidative toxicity via oestrogen receptor α signalling pathways.
Song Z; Han S; Pan X; Gong Y; Wang M
J Pharm Pharmacol; 2015 May; 67(5):720-30. PubMed ID: 25644078
[TBL] [Abstract][Full Text] [Related]
33. Role of sphingolipids in oestrogen signalling in breast cancer cells: an update.
Sukocheva O; Wadham C
J Endocrinol; 2014 Mar; 220(3):R25-35. PubMed ID: 24323911
[TBL] [Abstract][Full Text] [Related]
34. Prediction and analysis of ligands against estrogen related receptor alpha.
Chitrala KN; Yeguvapalli S
Asian Pac J Cancer Prev; 2013; 14(4):2371-5. PubMed ID: 23725143
[TBL] [Abstract][Full Text] [Related]
35. Estrogen Receptor α (ERα)-targeting Compounds and Derivatives: Recent Advances in Structural Modification and Bioactivity.
Guo WY; Zeng SM; Deora GS; Li QS; Ruan BF
Curr Top Med Chem; 2019; 19(15):1318-1337. PubMed ID: 31215379
[TBL] [Abstract][Full Text] [Related]
36. Modulation of tumorigenesis and oestrogen receptor-alpha expression by cell culture conditions in a stem cell-derived breast epithelial cell line.
Wang KH; Kao AP; Chang CC; Lee JN; Chai CY; Hou MF; Liu CM; Tsai EM
Biol Cell; 2010 Jan; 102(3):159-72. PubMed ID: 19895368
[TBL] [Abstract][Full Text] [Related]
37. Estrogen-related receptor-alpha antagonist inhibits both estrogen receptor-positive and estrogen receptor-negative breast tumor growth in mouse xenografts.
Chisamore MJ; Wilkinson HA; Flores O; Chen JD
Mol Cancer Ther; 2009 Mar; 8(3):672-81. PubMed ID: 19276159
[TBL] [Abstract][Full Text] [Related]
38. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
39. Xenoestrogens and the induction of proliferative effects in breast cancer cells via direct activation of oestrogen receptor alpha.
Recchia AG; Vivacqua A; Gabriele S; Carpino A; Fasanella G; Rago V; Bonofiglio D; Maggiolini M
Food Addit Contam; 2004 Feb; 21(2):134-44. PubMed ID: 14754635
[TBL] [Abstract][Full Text] [Related]
40. Neo-tanshinlactone selectively inhibits the proliferation of estrogen receptor positive breast cancer cells through transcriptional down-regulation of estrogen receptor alpha.
Lin W; Huang J; Liao X; Yuan Z; Feng S; Xie Y; Ma W
Pharmacol Res; 2016 Sep; 111():849-858. PubMed ID: 27491559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
